胰岛素联合罗格列酮或二甲双胍随机对照治疗对2型糖尿病患者血清氨基末端脑钠肽的影响

Effect of Insulin Plus Rosiglitazone or Metformin on Serum N-Terminal Pro-brain Natriuretic Peptide in Type 2 Diabetes Mellitus:A Randomized-Controlled Study

比较胰岛素联合罗格列酮治疗与胰岛素联合二甲双胍治疗对2型糖尿病患者血清氨基末端脑钠肽(NT-BNP)水平的影响,了解血清NT-BNP水平是否可以作为罗格列酮诱发心衰的预测指标。符合纳入标准2型糖尿病患者60例,随机分成A、B两组。A组给予胰岛素联合罗格列酮(4mg/d)治疗,B组给予胰岛素联合二甲双胍治疗,共8周,治疗前后分别测血清NT-BNP水平。结果,两组治疗前后血清NT-BNP平均水平无明显变化(P>0·05)。两组治疗前后血清NT-BNP差值比较无显著差异(P>0·05)。胰岛素联合罗格列酮组,3例出现水肿,其血清NT-BNP较治疗前升高108·99fmol/ml,无心衰病例发生。胰岛素联合罗格列酮和胰岛素联合二甲双胍治疗,对2型糖尿病患者血清NT-BNP无明显影响。血清NT-BNP是否可以作为罗格列酮治疗2型糖尿病患者诱发心衰的早期预测指标有待更多的观察。

This study was aimed to compare the effect of insulin plus rosiglitazone with that of insulin plus metformin on the level of serum N-terminal pro-brain natriuretic peptide(NT-BNP) in patients with type 2 diabetes mellitus, and to find out whether serum NT-BNP can be used as an index for predicting heart failure induced by rosiglitazone in the cases of type 2 diabetes mellitus. Sixty type 2 diabetic patients were recruited and were randomly divided into two groups: group A(n=30) received insulin plus rosigli...